Anbio Biotechnology
NNNN
5 hedge funds and large institutions have $894K invested in Anbio Biotechnology in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0.09% less ownership
Funds ownership: 0.16% → 0.07% (-0.09%)
50% less funds holding
Funds holding: 10 → 5 (-5)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
65% less capital invested
Capital invested by funds: $2.54M → $894K (-$1.65M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$51.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$389K |
| 2 |
Millennium Management
New York
|
-$264K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$257K |
| 4 |
Morgan Stanley
New York
|
-$236K |
| 5 |
HF
HRT Financial
New York
|
-$223K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $775K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $85.7K | +$51.9K | +1,889 | +197% |
|
3
BNP Paribas Financial Markets
Paris,
France
| $30.1K | -$39K | -1,419 | -59% |
|
4
Wells Fargo
San Francisco,
California
| $3.01K | – | – | – |
|
|
5
Morgan Stanley
New York
| $842 | -$236K | -8,582 | -100% |
|
|
6
Marshall Wace
London,
United Kingdom
| – | -$389K | -10,443 | Closed |
|
|
7
Millennium Management
New York
| – | -$264K | -7,080 | Closed |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| – | -$257K | -6,896 | Closed |
|
|
HF
9
HRT Financial
New York
| – | -$223K | -6,013 | Closed |
|
10
Bank of America
Charlotte,
North Carolina
| – | -$782 | -21 | Closed |
|
NNNN Hedge Fund Activity: Q4 2025 in Review
5 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q4 2025, worth a combined $894K — down 65% from $2.54M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NNNN and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $51.9K. The largest seller was Marshall Wace, exiting entirely with an estimated $389K sold.
- 5 institutional investors held Anbio Biotechnology (NNNN) as of Q4 2025, down from 10 in Q3 2025.
- Funds reported $894K of Anbio Biotechnology stock for Q4 2025, down 65% quarter-over-quarter.
- 0 funds opened new Anbio Biotechnology positions in Q4 2025 and 5 closed out, a net change of -5 holders.
- The largest Anbio Biotechnology buyer in Q4 2025 was UBS Group, an estimated $51.9K added.
- The largest Anbio Biotechnology seller in Q4 2025 was Marshall Wace, an estimated $389K sold.
Based on aggregated 13F filings for Q4 2025.